Use of Novel Oral Anticoagulants Post-cardioversion in Atrial Fibrillation: A Safety Review.

Simple item page
dc.contributor.authorMehra, S
dc.contributor.authorProdduturvar, P
dc.contributor.authorMarcu, Constantin B
dc.contributor.authorChelu, Mihail G
dc.date.accessioned2016-12-23T09:21:18Z
dc.date.available2016-12-23T09:21:18Z
dc.date.issued2015
dc.description.abstractAtrial fibrillation is considered the most common sustained arrhythmia worldwide, especially in geriatric population and is associated with significant morbidity and mortality. Arterial embolization is the most serious complication of atrial fibrillation. Vitamin K antagonists were the only form of oral anticoagulant medication approved for long-term use since 1940s, till the advent of three novel oral anticoagulants- dabigatran, rivaroxaban and apixaban. The new anticoagulants are more convenient to administer than warfarin. Pivotal trials of these drugs showed that they are not only as effective as warfarin, but also cause less intracranial bleeding. There is data emerging regarding the safety of these agents in the context of cardioversion. The purpose of this review is to examine the current published safety data for the use of novel oral anticoagulants around the time of cardioversion.en_US
dc.identifier.citationMehra S, Prodduturvar P, Marcu Constantin B, Chelu Mihail G. Use of Novel Oral Anticoagulants Post-cardioversion in Atrial Fibrillation: A Safety Review. British Journal of Medicine and Medical Research. 2015; 7(9): 718-722.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/180404
dc.language.isoenen_US
dc.source.urihttps://www.sciencedomain.org/metrics/8552en_US
dc.subjectNew oral anticoagulantsen_US
dc.subjectnon-valvular atrial fibrillationen_US
dc.subjectgeneticen_US
dc.subjectpolymorphismen_US
dc.subjectmutationsen_US
dc.subjectcardioversionen_US
dc.subjectechocardiogramen_US
dc.subjecttransesophagealen_US
dc.subjectthromboembolicen_US
dc.subjectintracranialen_US
dc.subjectbleedingen_US
dc.titleUse of Novel Oral Anticoagulants Post-cardioversion in Atrial Fibrillation: A Safety Review.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
bjmmr2015v7n9p718.pdf
Size:
258.17 KB
Format:
Adobe Portable Document Format
Description:
Review article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal of Advances in Medicine and Medical Research